{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:13:33Z","timestamp":1795180413342,"version":"4.10.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Science and Technology Research Foundation of Guangdong Province of China","award":["A2016623"],"award-info":[{"award-number":["A2016623"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>FLT-PET\/CT can accurately identify and locate functional bone marrow (FBM) with hematopoietic capability, the FBM were divided into two levels as FBM<jats:sub>1<\/jats:sub> (strongest hemopoietic ability region)and FBM<jats:sub>2<\/jats:sub> (moderate hemopoietic ability region) via FLT-PET\/CT. The purpose of this study was to explore the relationship between dose-volume parameters of pelvic FBM and hematologic toxicity (HT) during radiotherapy with or without concurrent chemotherapy for uterine cervical\/endometrial cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From December 2016 to September 2021, ninety-seven uterine cervical\/endometrial cancer patients received intensity-modulated radiation therapy were prospectively recruited in this single-arm, prospective, phase II trial. Blood counts were reviewed weekly during radiotherapy. Single- and multifactor regression methods were used to analyze the relationships between dose-volume parameters of FBM<jats:sub>1\/2<\/jats:sub> and grade\u2009\u2265\u20092 HT. ROC curves were used to determine the cutoff values for the dose-volume parameters of FBM<jats:sub>1\/2<\/jats:sub>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of grade\u2009\u2265\u20092 leukopenia, neutropenia, thrombocytopenia and anemia in patients during radiotherapy was 63.9%, 45.4%, 19.6% and 38.8% respectively, and the median occurrence time was the 29th, 42th, 35th and 31th day, respectively. Multivariate regression analysis showed that the D<jats:sub>max<\/jats:sub> of FBM<jats:sub>1<\/jats:sub> was significantly related to grade\u2009\u2265\u20092 leukopenia (OR\u2009=\u20091.277 95% CI 1.067\u20131.528, <jats:italic>P<\/jats:italic>\u2009=\u20090.008), D<jats:sub>mean<\/jats:sub> of FBM<jats:sub>2<\/jats:sub> was significantly related to grade\u2009\u2265\u20092 thrombocytopenia (OR\u2009=\u20091.262 95% CI 1.066\u20131.494, <jats:italic>P<\/jats:italic>\u2009=\u20090.007), and V<jats:sub>10<\/jats:sub> of FBM<jats:sub>1<\/jats:sub> was significantly related to grade\u2009\u2265\u20092 anemia (OR\u2009=\u20091.198 95% CI 1.003\u20131.431, <jats:italic>P<\/jats:italic>\u2009=\u20090.046). The incidence of grade\u2009\u2265\u20092 leukopenia for patients with FBM<jats:sub>1<\/jats:sub> D<jats:sub>max<\/jats:sub> &lt; 53\u00a0Gy was lower than that for patients with FBM<jats:sub>1<\/jats:sub> D<jats:sub>max<\/jats:sub> \u2265 53\u00a0Gy (53.4% vs. 95.8%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The incidence of grade\u2009\u2265\u20092 thrombocytopenia in patients with FBM<jats:sub>2<\/jats:sub> D<jats:sub>mean<\/jats:sub> &lt; 33\u00a0Gy was lower than that in patients with FBM<jats:sub>2<\/jats:sub> D<jats:sub>mean<\/jats:sub> \u2265 33\u00a0Gy (0 vs. 28.4%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The incidence of grade\u2009\u2265\u20092 anemia for patients with FBM<jats:sub>1<\/jats:sub> V<jats:sub>10<\/jats:sub>\u2009&lt;\u200995% was lower than that in patients with FBM<jats:sub>1<\/jats:sub> V<jats:sub>10<\/jats:sub>\u2009\u2265\u200995% (24.4% vs. 57.1%, <jats:italic>P<\/jats:italic>\u2009=\u20090.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Grade\u2009\u2265\u20092 HT usually occurs in the 4th week of radiotherapy for patients with uterine cervical\/endometrial cancer. The D<jats:sub>max<\/jats:sub> and V<jats:sub>10<\/jats:sub> of FBM<jats:sub>1<\/jats:sub> and the D<jats:sub>mean<\/jats:sub> of FBM<jats:sub>2<\/jats:sub> were significantly associated with the occurrence of grade\u2009\u2265\u20092 HT. The recommended optimal dose constraints were FBM<jats:sub>1<\/jats:sub> D<jats:sub>max<\/jats:sub> &lt; 53\u00a0Gy, V<jats:sub>10<\/jats:sub>\u2009&lt;\u200995%, and FBM<jats:sub>2<\/jats:sub> D<jats:sub>mean<\/jats:sub> &lt;33\u00a0Gy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02380-8","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T20:02:18Z","timestamp":1701115338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical\/endometrial cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Hongbo","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuquan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengrong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"5","key":"2380_CR1","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","volume":"31","author":"P Mauch","year":"1995","unstructured":"Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1319\u201339.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2380_CR2","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood.V89.7.2303","volume":"89","author":"M Mac Manus","year":"1997","unstructured":"Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood. 1997;89(7):2303\u201310.","journal-title":"Blood"},{"key":"2380_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13578-015-0057-3","volume":"5","author":"C Li","year":"2015","unstructured":"Li C, Lu L, Zhang J, et al. Granulocyte colony-stimulating factor exacerbates hematopoietic stem cell injury after irradiation. Cell Biosci. 2015;5:65.","journal-title":"Cell Biosci"},{"issue":"3","key":"2380_CR4","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ijrobp.2009.11.010","volume":"79","author":"BS Rose","year":"2011","unstructured":"Rose BS, Aydogan B, Liang Y, et al. Normal tissue complication probability modeling of acute hematologic toxicity in Cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(3):800\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2380_CR5","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.ijrobp.2009.12.025","volume":"79","author":"K Albuquerque","year":"2011","unstructured":"Albuquerque K, Giangreco D, Morrison C, et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for Cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys. 2011;79(4):1043\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2380_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","volume":"66","author":"LK Mell","year":"2006","unstructured":"Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in Cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(5):1356\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2380_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13014-020-01606-3","volume":"15","author":"J Huang","year":"2020","unstructured":"Huang J, Gu F, Ji T, Zhao J, Li G. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with Cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial. Radiat Oncol. 2020;15(1):180.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2380_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mp.15365","volume":"49","author":"D Wang","year":"2022","unstructured":"Wang D, Yin Y, Zhou Q, et al. Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in Cervical cancer patients with treated with pelvic irradiation. Med Phys. 2022;49(1):756\u201367.","journal-title":"Med Phys"},{"issue":"1","key":"2380_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijrobp.2013.01.017","volume":"86","author":"AH Klopp","year":"2013","unstructured":"Klopp AH, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86(1):83\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2380_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12094-017-1771-6","volume":"20","author":"YM Zhou","year":"2018","unstructured":"Zhou YM, Freese C, Meier T, et al. The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in Cervical cancer patients undergoing chemoradiation. Clin Transl Oncol. 2018;20(6):713\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"2380_CR11","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ijrobp.2008.04.046","volume":"71","author":"LK Mell","year":"2008","unstructured":"Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of Cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(5):1504\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2380_CR12","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","volume":"70","author":"LK Mell","year":"2008","unstructured":"Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(5):1431\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2380_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ijrobp.2016.11.027","volume":"97","author":"LK Mell","year":"2017","unstructured":"Mell LK, Sir\u00e1k I, Wei L, et al. Bone marrow-sparing intensity modulated Radiation Therapy with Concurrent Cisplatin for Stage IB-IVA Cervical Cancer: An International Multicenter Phase II clinical trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. 2017;97(3):536\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2380_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijrobp.2021.08.019","volume":"112","author":"CW Williamson","year":"2022","unstructured":"Williamson CW, Sir\u00e1k I, Xu R, et al. Positron Emission Tomography-guided bone marrow-sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: final results from the INTERTECC phase II\/III trial. Int J Radiat Oncol Biol Phys. 2022;112(1):169\u201378.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2380_CR15","first-page":"1592","volume":"47","author":"A Agool","year":"2006","unstructured":"Agool A, Schot BW, Jager PL, Vellenga E. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med. 2006;47(10):1592\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"2380_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.radonc.2011.01.025","volume":"99","author":"SM McGuire","year":"2011","unstructured":"McGuire SM, Menda Y, Ponto LL, Gross B, Juweid M, Bayouth JE. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiother Oncol. 2011;99(1):49\u201354.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2380_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1120\/jacmp.v15i4.4780","volume":"15","author":"SM McGuire","year":"2014","unstructured":"McGuire SM, Menda Y, Ponto L, et al. Spatial mapping of functional pelvic bone marrow using FLT PET. J Appl Clin Med Phys. 2014;15(4):129\u201336.","journal-title":"J Appl Clin Med Phys"},{"issue":"3","key":"2380_CR18","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/j.ijrobp.2020.07.2607","volume":"108","author":"H Chen","year":"2020","unstructured":"Chen H, Deng W, Zhong Q, et al. Dose-volume parameters of pelvic functional bone Marrows Predict Acute Hematological Toxicities during intensity-modulated Radiotherapy Concurrent with or without cisplatin for Cervical\/ endometrial Cancer: a prospective II study. Int J Radiation Oncology*Biology*Physics. 2020;108(3):e472\u20133.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"2","key":"2380_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ijrobp.2007.09.042","volume":"71","author":"W Small Jr","year":"2008","unstructured":"Small W Jr, Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and Cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):428\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2380_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijrobp.2009.10.075","volume":"79","author":"K Lim","year":"2011","unstructured":"Lim K, Small W Jr, Portelance L, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys. 2011;79(2):348\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1092","key":"2380_CR21","doi-asserted-by":"publisher","first-page":"20180005","DOI":"10.1259\/bjr.20180005","volume":"91","author":"S Lewis","year":"2018","unstructured":"Lewis S, Chopra S, Naga P, et al. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin. Br J Radiol. 2018;91(1092):20180005.","journal-title":"Br J Radiol"},{"issue":"17","key":"2380_CR22","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1002\/cam4.2601","volume":"8","author":"SB Wang","year":"2019","unstructured":"Wang SB, Liu JP, Lei KJ, et al. The volume of 99m tc sulfur colloid SPET-defined active bone marrow can predict grade 3 or higher acute hematologic toxicity in locally advanced Cervical cancer patients who receive chemoradiotherapy. Cancer Med. 2019;8(17):7219\u201326.","journal-title":"Cancer Med"},{"key":"2380_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bone.2014.02.018","volume":"63","author":"DE Green","year":"2014","unstructured":"Green DE, Rubin CT. Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. Bone. 2014;63:87\u201394.","journal-title":"Bone"},{"issue":"4","key":"2380_CR24","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1073\/pnas.1015350108","volume":"108","author":"X Cao","year":"2011","unstructured":"Cao X, Wu X, Frassica D, et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc Natl Acad Sci U S A. 2011;108(4):1609\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1073","key":"2380_CR25","doi-asserted-by":"publisher","first-page":"20160885","DOI":"10.1259\/bjr.20160885","volume":"90","author":"L Bazire","year":"2017","unstructured":"Bazire L, Xu H, Foy JP, et al. Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature. Br J Radiol. 2017;90(1073):20160885.","journal-title":"Br J Radiol"},{"issue":"15","key":"2380_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","volume":"340","author":"HM Keys","year":"1999","unstructured":"Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154\u201361.","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"2380_CR27","doi-asserted-by":"publisher","first-page":"58S","DOI":"10.1016\/j.amjmed.2003.12.013","volume":"116","author":"A Shander","year":"2004","unstructured":"Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence and outcomes of anemia in Surgery: a systematic review of the literature. Am J Med. 2004;116(Suppl 7):58S\u201369S.","journal-title":"Am J Med"},{"key":"2380_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1088\/0031-9155\/5\/3\/302","volume":"5","author":"ELLIS RE","year":"1961","unstructured":"ELLIS RE. The distribution of active bone marrow in the adult. Phys Med Biol. 1961;5:255\u20138.","journal-title":"Phys Med Biol"},{"issue":"4","key":"2380_CR29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","volume":"111","author":"P Damen","year":"2021","unstructured":"Damen P, Kroese TE, van Hillegersberg R, et al. The influence of severe Radiation-Induced Lymphopenia on overall survival in solid tumors: a systematic review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2021;111(4):936\u201348.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02380-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02380-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02380-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T20:06:23Z","timestamp":1701115583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02380-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2380"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02380-8","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Jiangmen central hospital, Guangdong Province, China (Approval number: 2016-05, date of approval:11 January 2016). We certify that the study was performed in accordance with the 1964 declaration of Helsinki and later amendments. And the written informed consent was obtained from all the participants prior to the enrollment of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}